Hickman Peter E, Koerbin Gus, Simpson Aaron, Potter Julia M, Hughes David G, Abhayaratna Walter P, West Nic, Glasgow Nicholas, Armbruster David, Cavanaugh Juleen, Reed Maxine
ACT Pathology, The Canberra Hospital, Garran, ACT, Australia.
Australian National University Medical School, Garran, ACT, Australia.
Clin Endocrinol (Oxf). 2017 Jan;86(1):108-112. doi: 10.1111/cen.13143. Epub 2016 Jul 21.
Thyroid disease can be subtle in its presentation, and TSH reference intervals may be artefactually increased by including persons with subclinical thyroid disease. We have therefore used a thyroid disease-free population to determine TSH and fT4 reference intervals.
Apparently healthy subjects were assessed by health questionnaire, drug history, clinical assessment and measurement of thyroid antibodies.
Healthy subjects in a community setting.
TSH, free T4, antithyroglobulin and anti-TPO were measured on the Abbott Architect analyser. Subjects with clinical abnormalities, consumption of thyroid-active medications or with thyroid antibodies above the manufacturer-quoted reference intervals were excluded. TSH and fT4 data were log-transformed, and the central 95% was used to calculate reference intervals. We assessed whether these data were normally distributed. We compared samples spanning the reference intervals for both TSH and fT4 between different assays looking at biases.
From a population of 1,606 subjects, 140 males (18%) and 284 females (34%) were excluded. The central population 95% for TSH was 0·43-3·28 mU/l and for fT4 10·8-16·8 pmol/l. There were no age- or sex-related differences. For both analytes, the distribution was not significantly different to a Gaussian distribution (P > 0·05). For 5 commonly used assays for TSH, the maximum difference in the upper limit of the TSH reference interval was 0·48 mU/l and for fT4 the maximum difference for the upper reference limit was 4·1 pmol/l.
A substantial proportion of apparently healthy persons have subclinical thyroid disease. These subjects must be excluded for any thyroid hormone reference interval studies.
甲状腺疾病的表现可能较为隐匿,将亚临床甲状腺疾病患者纳入会人为地提高促甲状腺激素(TSH)参考区间。因此,我们采用无甲状腺疾病的人群来确定TSH和游离甲状腺素(fT4)参考区间。
通过健康问卷、用药史、临床评估及甲状腺抗体检测对表面健康的受试者进行评估。
社区环境中的健康受试者。
使用雅培Architect分析仪检测TSH、游离T4、抗甲状腺球蛋白和抗甲状腺过氧化物酶(TPO)。排除有临床异常、服用甲状腺活性药物或甲状腺抗体高于制造商给出的参考区间的受试者。对TSH和fT4数据进行对数转换,并用中间95%的数据计算参考区间。我们评估了这些数据是否呈正态分布。我们比较了不同检测方法中TSH和fT4参考区间内的样本,观察偏差情况。
在1606名受试者中,排除了140名男性(18%)和284名女性(34%)。TSH的中间人群95%参考区间为0.43 - 3.28 mU/l,fT4为10.8 - 16.8 pmol/l。不存在年龄或性别相关差异。对于这两种分析物,其分布与高斯分布无显著差异(P > 0.05)。对于5种常用的TSH检测方法,TSH参考区间上限的最大差异为0.48 mU/l,fT4参考区间上限的最大差异为4.1 pmol/l。
相当一部分表面健康的人患有亚临床甲状腺疾病。在任何甲状腺激素参考区间研究中,必须排除这些受试者。